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Plasma membrane expressionAdenosine is a well known neuromodulator in the central nervous system. As a consequence, adenosine can
be beneﬁcial in certain disorders and adenosine receptors will be potential targets for therapy in a variety of
diseases. Adenosine receptors are G protein-coupled receptors, and are also expressed in a large variety of
cells and tissues. Using these receptors as a paradigm of G protein-coupled receptors, the present review
focus on how protein–protein interactions might contribute to neurotransmitter/neuromodulator regula-
tion, based on the fact that accessory proteins impinge on the receptor/G protein interaction and therefore
modulate receptor functioning. Besides affecting receptor signaling, these accessory components also play a
key role in receptor trafﬁcking, internalization and desensitization, as it will be reviewed here. In conclusion,
the ﬁnding of an increasing number of adenosine receptors interacting proteins, and specially the molecular
and functional integration of these accessory proteins into receptorsomes, will open new perspectives in the
understanding of particular disorders where these receptors have been proved to be involved.
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Table 1
Adenosine receptors in the brain.
Receptor Adenosine
afﬁnity
G
protein
Transduction
mechanismsa
Physiological actions
in brain
A1R ∼ 70 nM Gi1,2,3 Inhibits AC (↓cAMP)
Activates PLC (↑IP3/DAG)
Inhibits synaptic
transmission;
hyperpolarizes
neurons
Activates PLA2 (↑AA)
Activates PLD (↑PEtOH)
Activates GIRKs
Inhibits Ca2+ channels
Go
A2AR ∼ 150 nM GSb Activates AC (↑cAMP) Facilitates
transmitter release;
regulation of
sensorimotor
integration in basal
ganglia
Golf Activates AC (↑cAMP)
G15,16c ↑IP3
Inhibits Ca2+ channels
A2BR ∼ 5000 nM GSb Activates AC (↑cAMP)
Activates Ca2+ channels
Increases in cAMP
in brain slices
Gq/11c Activates PLC (↑IP3/DAG)
A3R ∼ 6500 nM Gi2,3 Inhibits AC (↓cAMP) Uncouples A1R and
mGlu receptorsGq/11 Activates PLC (↑IP3/DAG)
a AC, adenylyl cyclase; PLC, phospholipase C; IP3, inositol triphosphate; DAG,
diacylglycerol; PLA2, phospholipase A2; PEtOH, phosphatidylethanol; GIRKs, G protein-
dependent inwardly rectifying K+ channels; AA, arachidonic acid.
b Main mechanism of coupling.
c Receptor transfected cell system.
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Since Drury and Szent-Györgyi found 80 years ago that adenosine
produced profound hypotension and bradycardia, as well as it affected
kidney function in mammals [1], the physiological roles and potential
therapeutic use of adenosine have been largely revised [2,3].
Adenosine is mainly produced by degradation of ATP and in lessen
extend by S-adenosyl-L-homocysteine (SAH) metabolism. Also,
adenosine can be formed extracellularly by the breakdown of ATP.
Once it has been generated, it can either be eliminated out of the cells
by means of ubiquitous nitrobenzylthioinosine-sensitive equilibrative
nucleoside transporters (ENTs) or intracellularly phosphorylated to
form AMP. In addition, adenosine can react with L-homocysteine to
form SAH. And ﬁnally, both intra- and extracellular adenosine can be
deaminated to form inosine by the action of intra- and ecto-adenosine
deaminase, respectively.
Regarding adenosine functions, it has been largely considered a
retaliatory metabolite [4] that increases oxygen supply and decreases
oxygen consumption, thus modulating a large array of physiological
processes including respiratory regulation, hormone action, neural
function, platelet aggregation, lymphocyte differentiation and vascu-
lar tone. For instance, adenosine is able to induce the dilation of
coronary arteries, but it can also lead to the contraction of other blood
vessels like the ones in the kidney, resulting in a decreased renal
ﬁltration. Also, adenosine exerts a negative chronotropic and dromo-
tropic effect on the heart, as well as it mediates the inhibition of
neurotransmitters release and lipolysis. Overall, it has been assumed
that this purine nucleoside is a mediator of metabolic distress, thus
having considerable impact on homeostatic cellular functioning.
In 1972, it was shown that adenosine was released from brain
slices upon electrical stimulation [5]. Interestingly, the released
adenosine produced an increase in the intracellular levels of cAMP,
an effect that was antagonized by methylxanthines such as caffeine
and theophylline [6]. This fact was also observed in the heart [7].
Collectively, these observations constituted the ﬁrst evidence sug-
gesting that adenosine exerted its effects via speciﬁc plasma
membrane receptors. Afterwards, it was demonstrated that the so
described antilipolytic effect of adenosine on fat cells occurred with a
concomitant reduction in cAMP [8]. The dual effects of adenosine on
cAMP formation were further substantiated when it was demonstrat-
ed that adenosine could either inhibit or stimulate adenylyl cyclase.
Overall, these observations ended with the ﬁrst subclassiﬁcation of
adenosine receptors into Ri and Ra [9], or alternatively, A1 and A2
adenosine receptors [10].
In the Central Nervous System (CNS), adenosine has been shown
to play a regulatory role, acting as a presynaptic, postsynaptic and/or
non-synaptic neuromodulator [11]. Extracellular adenosine in the
brain is related to the intracellular concentration of adenosine and
nucleotides, such as ATP, AMP and cAMP [12]. In some brain areas, like
the hippocampus, most of the extracellular adenosine seems to
depend mostly on intracellular adenosine, the concentration of which
is related to the rate of breakdown and synthesis of ATP [12]. Thus,
adenosine is released as a neuromodulator [13] by the effector cells in
response to an increased metabolic demand [14]. However, in the
striatum, it has been suggested that the main source of extracellular
adenosine is intracellular cAMP [15], which is metabolized to AMP by
means of phosphodiesterases and then to adenosine by the ectoen-
zyme 5′nucleotidase. Since cAMP can only be generated by the action
of the enzyme adenylyl cyclase, striatal extracellular adenosine would
mostly reﬂect an increased activation of receptors positively linked to
adenylyl cyclase.
2. Adenosine receptors
Adenosine mediates its actions by means of activation of speciﬁc G
protein-coupled receptors (GPCRs), for which four subtypes (A1R,A2AR, A2BR and A3R) have been identiﬁed so far. These receptors have
a distinctive pharmacological proﬁle, tissue distribution and effector
coupling [16], and its functioning has been extensively studied in the
CNS (Table 1). The GPCRs comprise the largest family of membrane-
bound receptors, containing more than 1000 different members
which represent over 1% of the genome in vertebrates [17]. From a
phylogenetic point of view, these receptors can be classiﬁed into ﬁve
main families (GRAFS classiﬁcation system), namely glutamate,
rhodopsin, adhesion, frizzled/taste 2 and secretin [18]. Adenosine
receptors (ARs) belong to the rhodopsin family, also called family I or
A [19]. This receptor family has more than 700 different members that
share some phylogenetic and intrinsic characteristics. For instance,
within their sequence, all adenosine receptors contain the widely
conserved NPxxY(x)5,6F and the DRYmotifs [20,21]. Thus, adenosine-
mediated conformational change in the ARs core domain affects the
conformation of the intracellular loops, which in turn determines the
binding and activation of speciﬁc G proteins (Table 1). Stimulation of
G proteins is then responsible for activation of different intracellular
signaling pathways associated to adenosine function (Table 1).
Interestingly, A1Rs and A2ARs are primarily responsible for the
central effects of adenosine [22]. The most abundant and homoge-
neously distributed adenosine receptor in the brain is the A1R, which
is functionally coupled to members of the pertussis toxin-sensitive
family of G proteins (Gi1, Gi2, Gi3 and Go) and whose activation
regulates several membrane and intracellular proteins such as
adenylyl cyclase, Ca2+ channels, K+ channels and phospholipase C
(Table 1) [23]. On the other hand, A2AR is expressed at high levels in
only a few regions of the brain, namely primarily striatum, olfactory
tubercle and nucleus accumbens [15]. A2ARs are mostly coupled to
Gs/Golf proteins [24], thus activating adenylyl cyclase which in turn
converts ATP into AMPc (Table 1). Depending on the cell type studied,
the A2AR may also signal via a pathway that might be independent of
heterotrimeric G proteins; such is the case of the activation of the
mitogen-activated protein kinase (MAPK) signaling cascade [25].
Next, the A2BR is positively coupled to adenylyl cyclase and PLC
through a Gs and Gq protein, respectively [2] (Table 1). A2BR is thought
to be fairly ubiquitous in the brain, and the association of this receptor
to speciﬁc physiological or behavioral responses remains quite
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Lastly, the A3R has also been found to be coupled to classical second-
messenger pathways such as inhibition of adenylyl cyclase, stimula-
tion of PLC and calcium mobilization (for review see [2]) (Table 1).
Finally, it is important to mention at this point that different classes of
proteins, other than G proteins, are being recognized to interact with
GPCRs. The binding of GPCRs to some of these proteins will determine
interactions with different intramembrane and intracellular elements,
which in turn will result, not only in changes in receptor localization
and function, but also in G protein-independent signaling [27]. These
proteins include serine–threonine or tyrosine protein kinases, β-
arrestins and scaffolding proteins within others.
3. Adenosine receptors interacting proteins (ARIPs)
In the present work, we underscore the ARs ability to interact with
proteins different from receptors and how these accessory proteins
affect receptor function, in the view that these protein–protein
interactions might control receptor trafﬁcking (e.g. cell surface
expression, internalization and recycling) and function (e.g. G
protein-coupling and desensitization) [27]. In addition, the stoichi-
ometry, the afﬁnity of these partners and the presence of cellular
modulators (e.g. Ca2+) can determine the dynamics of these protein–
protein interactions. Finally, it is proposed that the intracellular
portions of adenosine receptors, namely the C-terminal tail and
intracellular loops, might become signal integrators where interacting
proteins would be associated or dissociated depending on cellular
inputs, thus making up the adenosine receptorsome.
3.1. Adenosine A1 receptor interacting proteins (A1RIPs)
Within the numerous neurophysiological actions of adenosine, the
inhibition of glutamate neurotransmission has been largely studied in
several brain regions [22]. This adenosine-mediated glutamate release
inhibition might be a consequence of the activation of presynaptic
A1Rs, which on its turn lead to a direct inhibitory effect of G protein
βγ-subunits on voltage-dependent Ca2+ channels [28,29]. Thus,
presynaptic A1Rs are the prototype of GPCRs the stimulation of
which decreases the probability of neurotransmitter release (Table 1).
On the other hand, the A1R turns out to be the predictable example of
GPCR where the identiﬁcation of interacting proteins other than the
typical GPCR-associated proteins (e.g. G proteins, β-arrestin, GRKs,
etc.) became successful. For instance, four A1RIPs have been described
so far, namely adenosine deaminase (ADA), heat shock cognate
protein 73 (HSC-73), Caveolin-1 and Protein 4.1.
3.1.1. Adenosine deaminase (ADA)
ADA is the enzyme that metabolizes the physiological agonist of
adenosine receptors, thus reducing the effective concentration of
adenosine in the cellular milieu and precluding adenosine-mediated
receptor stimulation. In addition, it has been demonstrated that ADA
behaves like an ecto-enzyme that is anchored to the cell surface
through different plasmamembrane proteins [30]. Interestingly, apart
from being the enzyme that can deaminate extracellular adenosine,
ADA can also have a non-enzymatically role through direct protein–
protein interactions [31]. Firstly, by means of confocal laser micros-
copy, co-immunoprecipitation and afﬁnity chromatography experi-
ments performed in DDT1MF-2 cells, an ADA/A1R interaction was
demonstrated [32], and it was shown to occur within the extracellular
loops of the receptor (Fig. 1). Subsequently, the existence of this
interaction in native cell membranes was also conﬁrmed, where it
seemed that ADA was necessary for the coupling of A1R to
heterotrimeric G proteins [32,33]. Moreover, the ADA/A1R complex
was found in the cell-surface of cortical cultured neurons [34], and
afterwards it was suggested that ADAwould be targeted to the plasma
membrane by A1R [35].The proposed physiological role of such protein–protein interaction
is tomake receptorsmore sensitive to adenosine. Thus, this heterotypic
interaction would be necessary for A1Rs to achieve high-afﬁnity
binding of agonists and subsequently for allowing efﬁcient coupling
to the signal transduction machinery. In fact, it was recently
demonstrated that human ADA markedly enhanced the agonist and
antagonist afﬁnity and abolished the negative cooperativity on agonist
binding to human striatal A1Rs [36]. In addition, apart from reducing
the adenosine concentration and preventing A1R desensitization, ADA
binds to A1R and behaves as an allosteric effector that markedly
enhances agonist afﬁnity and increases receptor functionality (Fig. 1).
Interestingly, when the enzymatic activity of ADA was knocked down
by incubation of the enzyme with low Hg2+ concentrations, an ADA/
A1R interaction was still conﬁrmed, thus suggesting that this
interaction would be enzymatic activity-independent and proposing
the contention that the docking of ADA to A1Rmight promote receptor
conformational changes that would allow a more efﬁcient receptor-
mediated signaling [32,36,37]. On the other hand, in cell-based assays
performed in different cell lines, the aggregation of both A1R and ADA
was reported after agonist challenge,which preceded the translocation
of both proteins into intracellular compartments. These results
suggested that the receptor–enzyme complex was sufﬁciently stable
to allow the simultaneous internalization of both proteins [37]. In
addition, preincubationwith an A1R agonist resulted in co-aggregation
of the dopamine D1 receptor (D1R) and A1R together with ADA in cells
expressing both receptors, suggesting that after A1R agonist challenge a
higher-order oligomeric structure leaded by A1R was formed [35].
Indeed,more researchwill be needed to unravel themolecularmecha-
nism by which ADA mediates the formation of a D1R/A1R oligomer as
this might have dramatic consequences in adenosine–dopamine
functional cross-talk. Precisely, this information will become relevant
to understand the molecular basis of some antagonistic adenosine–
dopamine interactions in the central nervous system that might be
relevant in the treatment of some CNS pathological conditions.
3.1.2. Heat shock cognate protein 73 (HSC-73)
A different A1R interacting protein, a chaperone protein, which has
been shown to play a key role in ligand binding and receptor signaling,
is the heat shock cognate protein 73 (HSC-73). Heat shock proteins
(HSPs), or stress proteins, are highly conserved and present in all cells
of all organisms. HSPs, also known as chaperones, play crucial roles in
the folding/unfolding of proteins, assembly of multiprotein com-
plexes, transport/sorting of proteins into correct subcellular compart-
ments, cell-cycle control and signaling, and protection of cells against
stress/apoptosis (for review see [38]). The 70-kDa members of the
HSPs family, including HSC-73, have been found to play a role in the
movement of proteins into the nucleus, mitochondria, endoplasmic
reticulum and lysosome (for review see [38]). HSC-73, speciﬁcally, has
been observed to facilitate the transport of proteins into the lysosome
after the withdrawal of serum from cells in culture. HSC-73 has
additional cellular functions apart from its role as a molecular
chaperone, namely it associates with cell cycle regulatory proteins,
retinoblastoma, p53 and Bcl-2 and also it has an ATPase activity for the
uncoating of clathrin-coated vesicles during endocytosis and vesicle
recycling (for review see [38]).
The interaction betweenHSC-73 and A1R, which takes placewithin
the third intracellular loop of the receptor, reduces agonists binding
and also prevents receptor-G protein activation (Fig. 1), this last
action being completely prevented by ADA, the extracellular receptor
partner. In fact, although ADA interacts extracellularly and HSC-73
interacts in the cytoplasmic side of the receptor, it seems that both
proteins compete for binding to A1R, thus modulating the function-
ality of the receptor [39].
On the other hand, it has been described that the HSC-73/A1R
interaction might also be implicated in A1R trafﬁcking and receptor
downregulation. A distinctive co-distribution of HSC-73 and A1R, but
Fig. 1. Schematic representation of A1R interaction with ADA, HSC, Caveolin-1 and Protein 4.1 proteins. Proposed interacting model where ADA interacts with the extracellular
domain and HSC-73 with the third intracellular loop of the receptor. Caveolin proteins homo- and hetero-oligomerize and form caveolae. The differential segregation of lipids in
caveolae, glycosphigolipids (pink) in the outer face of the plasma membrane and cholesterol in the inner face of the plasma membrane is also depicted in the ﬁgure. Protein 4.1G
participates in receptor plasma membrane anchoring and signaling. Cartoon diagrams are from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (www.
pdb.org) with the following references: G protein heterotrimer (PDB ID: 1gg2); ADA (PDB ID: 1vﬂ); HSC (PDB ID: 3fzf); Protein 4.1 (PDB ID: 1gg3). The schematic diagrams are
prepared by using PyMOL (The PyMOL Molecular Graphics System. DeLano Scientiﬁc, San Carlos, CA, U.S.A.). ⁎Necessary for internalization.
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family, was detected in speciﬁc regions of rat cerebellum and in the
soma of cortical neurons but not in dendrites or synapses [39]. Related
to this, and by means of confocal microscopy, it was observed that
chronically agonist-treated cells led to internalization of the A1R into
intracellular vesicles, some of them also containing HSC-73 [37]. In
conclusion, it seems reliable that HSC-73, without being the major
responsible is a necessary accessory protein to ensure the correct
function of A1Rs, since it is implied in all the receptor's cycle, from
agonist binding and signal transduction to receptor down-regulation.
3.1.3. Caveolin-1
Another conﬁrmed A1R interacting protein is caveolin-1. This
protein has been proposed to be involved in receptor anchoring,
trafﬁcking and down-regulation (Fig. 1), thus complementing the
function of GRKs and β-arrestins. Lipid rafts are divided into twomain
structural types: caveolae, which are ﬂask-like invaginations of the
plasma membrane containing caveolin proteins, and planar lipid raft.
Caveolae are present in most cell types but are especially abundant in
adipocytes, endothelial cells, ﬁbroblasts and smooth muscle cells [40].
In adipocytes and smoothmuscle cells, they represent up to 20% of the
total plasma membrane surface area. The main membrane proteins
present in caveolae are caveolins, which are necessary for caveolae
formation [41] and constitute, as amatter of fact, themolecularmarker
for these domains. Caveolin proteins (-1, -2 and -3) have cytoplasmicN
and C termini palmitolylation sites, and a scaffolding domain that
facilitates interaction and organization of signaling molecules [42].
Although these three mammalian subtypes of caveolin proteins are
similar in structure and function, they differ in tissue distribution;while caveolin-1 and -2 are abundant in caveolae-rich non-muscle
cells, caveolin-3 is found in skeletal muscle and in some smooth-
muscle cells [43]. The formation of caveolae by caveolin involves
oligomerization and association of these proteins with cholesterol-
rich lipid-raft domains. For instance, caveolin-1 binds to one or two
cholesterol molecules [44] and it is also palmitoylated in the C-
terminal domain [45]. Interestingly, caveolae are disrupted when
cholesterol is depleted in the cell, suggesting a key role of caveolin/
cholesterol interaction on caveolae formation [46]. Nevertheless,
caveolae are involved in cellular processes such as signal transduction
and receptor-mediated transport, including endocytosis, transcytosis
and potocytosis. As a consequence, it has been proposed that caveolae
serve as organizing hubs for cellular signal transduction, according to
which the signaling machinery found in caveolae would be upstream
of constituents as GPCRs, receptor tyrosine kinases and steroid
hormone receptors, and downstreamof components as heterotrimeric
and low-molecular-weight G proteins, effector enzymes and ion
channels. Consequently, it is believed that caveolae in general and
caveolin proteins in particular might be necessary to provide a
coordinated and efﬁcient signal transduction, thus their altered
localization or expression of signaling molecules in lipid rafts (e.g.
caveolae) might be at the rear of diseases associated with aberrant
signaling (for review see [42]). It is important to mention here that
while lipid rafts/caveolae domains might facilitate Gαi-coupled
receptor-mediated signaling (e.g. A1R) for some Gαs-coupled recep-
tors, these domains might have an opposite effect, thus being highly
effective in silencing Gαs functioning (e.g. cAMP production) and
mediatingGαs internalization [47]. Therefore, one should take this into
account when the functional effects of caveolae into A1R and A2AR are
13F. Ciruela et al. / Biochimica et Biophysica Acta 1798 (2010) 9–20studied as these receptors are coupled to Gαi and Gαs, respectively
(Table 1). Interestingly, a direct interaction between caveolin-1 and
the C-terminal domain of A1R was demonstrated by means of pull
down experiments and co-localization assays [37,48,49] (Fig. 1).
Moreover, it was reported that agonist-induced internalization of the
stable complex ADA/A1R was mediated by clathrin-independent
endocytosis. Thus, detailed electron microscopy in DDT1MF-2 cells
revealed that ADA/A1R complexes internalized through caveolae and
that these complexes were differentially sorted in intracellular
endosomes which were recycled back to the plasma membrane
separately [49]. Overall, these results indicate that desensitization and
internalization of A1R are modulated by ADA and both proteins
internalize after agonist challenge via non-coated vesicles, namely
caveolae, due to the caveolin-1/A1R interaction (Fig. 1).
3.1.4. Protein 4.1G
The last described adenosine A1R interacting protein is a member
of the 4.1 family of cytoskeletal-associated proteins, the protein 4.1G.
The protein 4.1 superfamily is classiﬁed into two main groups
according to their cellular expression pattern: the red blood cells
which express an erythroid form, also called 4.1R, and the non-
erythroid cells that present the 4.1G (general type), 4.1B (brain type)
and 4.1N (neuron type) forms. Despite being encoded by different
genes, proteins 4.1R, 4.1G, 4.1N and 4.1B all share similar structural
features, such as the presence of three highly conserved domains: a N-
terminal conserved FERM (Four.1 protein, Ezrin, Radixin, Moesin)
domain that links this cytoskeletal scaffold to the plasma membrane
via interactions with band 3 and glycophorin C, a spectrin–actin-
binding domain (SABD) that potentiates the interactions of spectrin
tetramers with F-actin and a C-terminal domain (CTD) that binds
FKBP13 (13 kDa FK506-binding protein) [50]. These multifunctional
proteins are critical components of the spectrin/actin cytoskeleton
and provide attachments between cytoskeleton and cell membranes,
thus playing an important structural and regulatory role in the
stabilization and assembly of these membranes.
Protein 4.1G binds to the third intracellular loop of A1R (Fig. 1), and
is involved in the trafﬁcking and down-regulation of the receptor [51].
As the spectrin–actin-binding domain of protein 4.1 G can form a
complexwith actin and spectrin, it is believed that protein 4.1 Gwould
anchor associated molecules, such as intramembranous proteins (e.g.
A1R), to the cytoskeleton. Lu and collaborators showed that protein
4.1G, by interacting with A1R (Fig. 1), reduced receptor-mediated
inhibition of cAMP accumulation and intracellular calcium release,
thus interferingwith the receptor signal transduction [51]. In addition,
protein 4.1G also altered the cell-surface expression of the receptor.
Interestingly, by means of immunostaining techniques, it was
demonstrated that in the CNS protein 4.1 G co-localized with markers
for microglia, such as CD45, OX-42 and ionized calcium-binding
adapter molecule 1 (Iba1), but not with markers for neuronal or other
glial cells [52]. In the samework, a co-localization between protein 4.1
G and A1R in mouse cerebrum was also shown [52], leading to the
belief that a further understanding of the protein 4.1 G distribution in
the CNS might help to clarify some of the functions of A1Rs.
3.2. Adenosine A2A receptor interacting proteins (A2ARIPs)
Quite the opposite to A1Rs, the adenosine A2 receptors subtype has
been extensively shown to have an excitatory action [53]. The
stimulation of A2ARs results in a calcium-dependent release of
glutamate and acetylcholine, by means of a mechanism that may
involve P-type channels [54] (Table 1). However, due to the fact that
A1Rs are more abundant and show higher afﬁnity for adenosine
(Table 1), the A1Rs effects (e.g. reduced excitotoxicity by reducing
glutamate release [54]) prevail under most of circumstances.
Nevertheless, some evidences indicate that these two receptors,
which are coupled to apparently opposite signaling pathways, whenco-expressed in the same cells such as in glutamatergic neurons of the
hippocampus [55] and striatum [56] might establish a molecular and/
or functional cross-talk [57,58]. Indeed, it has been shown that A2AR
and A1R oligomerize when co-expressed in the same cell (e.g. striatal
neurons) [56], thus suggesting that these two receptors might form
part of a shared molecular transduction complex or signalosome.
Therefore, the A2AR/A1R heterodimer will allow the A2AR to overcome
the A1R functional dominance by means of an intramembrane
receptor–receptor communication phenomenon where the A2AR
activation will promote a transinhibition of A1R function [56]. Within
this line of inquiry, it is laudable to hypothesize that A1R and A2AR
interacting proteins might potentially impinge in this intramembrane
receptor–receptor communication. Thus, these accessory proteins, by
driving receptor cell surface expression and plasma membrane
anchoring, might participate directly in the regulation of this
transconformational-transinhibitory switch, a phenomenon that will
only occur in speciﬁc subcellular domains were these two receptors
concur. Indeed, A1R and A2AR interact with F-actin binding proteins
(e.g. Protein 4.1 and α-actinin, respectively) that anchor receptors to
the cell surface by using the F-actin cytoskeleton. Conversely, it is also
feasible that the stimulation of a protomer within the A2AR/A1R
heteromer can in theory modulate not only the interaction with its
own accessory proteins but also to impinge in the counterpart
protomer's ability to interact with other proteins. Overall, the in vivo
existence of an A2AR/A1R heteromer would allow adenosine to exert a
ﬁne-tuning modulation of glutamatergic neurotransmission, provid-
ing a switch mechanism by which low and high concentrations of
adenosine would inhibit and stimulate, respectively, glutamate
release [59]. Thus, the role of A2AR/A1R interacting proteins in this
switch mechanism will constitute by sure an issue to be study in the
future.
Whereas A2BR is widely spread within the brain, the A2AR is
primarily located in the dopamine-rich areas of the basal ganglia, as
well as in the nucleus accumbens and olfactory bulb [60]. In these brain
areas, the A2ARs are involved in processes that include neuronal
plasticity and development. Interestingly, A2AR antagonists have been
shown to possess strong neuroprotective effects as well as to prevent
apoptosis. Consequently, in recent years this subtype of adenosine
receptor has been the centre of a growing number of studies because
of its potential therapeutic use [2,3].
The intracellular carboxyl-terminal tail of the A2AR is unusually
long when compared to the C-terminal tail of the other adenosine
receptors: 122 amino acids in contrast to the 34 residues of the A1R,
the 39 of the A2BR or the 34 of the A3R. Thus, by taking advantage of
the yeast two-hybrid (YTH) screening methodology and by using this
long A2AR C-terminal tail as bait, several binding partners for the
receptor have been found. Accordingly, the A2AR C-terminal tail has
been shown to function as a binding site for several proteins, namely
α-actinin, Arf nucleotide site opener (ARNO)/cytohesin-2, ubiquiting-
speciﬁc processing protease (USP4), translin-associated protein-X
(TRAX) and Neuronal Calcium-Binding Protein 2 (NECAB2) (Fig. 2).
3.2.1. α-actinin
It has been recently demonstrated that A2AR anchors to the actin
cytoskeleton through a direct interaction of the receptor C-terminal
tail with α-actinin (Fig. 2) [61]. α-actinin, discovered over more than
40 years ago as a component of the skeletal muscle [62], is a major F-
actin cross-linking protein composed of two identical anti-parallel
rod shaped peptides that bind actin ﬁlaments in a parallel fashion
(Fig. 2), thus playing a key role in bundling actin ﬁlaments in
multiple cell-type and cytoskeleton frameworks. Each α-actinin
monomer has three functionally distinct domains: the N-terminus,
containing two calponin homology domains (CH) that mediate the
interaction with actin, a central region composed of four spectrin-
like motifs (SPEC) and the C-terminus which contains EF-hand
domains (EFH), thus making the protein sensible to calcium ions (for
Fig. 2. Schematic representation of A2AR interaction with a-actinin, ARNO, TRAX, USP and NECAB. The schematic cartoon of the A2AR structure parallel to the plasma membrane is
adapted from [128] (PDB ID: 3eml). Other cartoon diagrams from the RCSB are: Actinin (PDB ID: 1sjj); ARNO (PDB ID: 1r8s); USP/UBP (PDB ID: 1nbf); USP/UBP (PDB ID: 1nbf). The
schematic diagrams are prepared has described in Fig. 1. §Promote A2AR long lasting ERK1/2 activation.
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muscle isoforms (α-actinin-1 and α-actinin-4) can bind calcium
ions, the muscle isoforms (α-actinin-2 and α-actinin-3) do not [64].
Thus, the only described functional difference between these α-
actinin isoforms is the fact that the binding of the non-muscle
isoforms to F-actin is calcium sensible whereas the muscle isoforms
are calcium insensitive [65]. Interestingly, α-actinin has emerged as a
major multivalent platform for a large number of protein–protein
interactions, thus apart from its interaction with actin ﬁlaments it
has been described to interact with several cytoskeletal and
regulatory proteins [64,66]. On the other hand, while the A2AR was
the ﬁrst GPCR shown to bind α-actinin [61], other receptors and ion
channels have also been found to interact with α-actinin, namely
Kv1-type potassium channels [67], ATP-gated ion channels P2X7 [68],
glutamate NMDA receptors [69], L-type calcium channel [70],
policystin-2 [71] and metabotropic glutamate receptor type 5 [72].
Thus, although the precise regulatory role of these interactions
remains to be established, it is tempting to assume that the existence
of such protein complexes is involved either in the anchoring of
those transmembrane proteins to speciﬁc subcellular locations or in
the targeting of α-actinin to speciﬁc functional plasma membrane
domains. For instance, it has been described that under resting cell
conditions, α-actinin is bound to NMDA receptor causing a decrease
of the receptor channel shut time, which results in an increased open
probability (Popen). When the intracellular calcium concentration
increases during neuronal excitation, α-actinin dissociates and
calmodulin binds to the receptor, ultimately resulting in a reduction
in Popen [73]. Interestingly, the NMDA/α-actinin-2 interaction was
reported in rat striatum [69], precisely where the A2AR is particularly
concentrated. In these rat striatal neurons, the stimulation of A2AR
produced an inhibition of NMDA currents, and since the treatmentwith an actin depolymerizing agent (e.g. cytochalasin B) precluded
this A2AR-mediated inhibitory effect [74], it could be concluded that
this mechanism of action was dependent of an intact α-actinin/actin
cytoskeleton. Hence, it is likely that in the rat striatum the actin
cytoskeleton in general and α-actinin particularly play a key role in
the A2AR-mediated functional regulation of NMDA action. Future
work will be needed to elucidate the potential role of these protein–
protein interactions in speciﬁc pathological conditions were these
two receptors might be involved, for instance in Parkinson's disease.
Furthermore, the A2AR structural dependence of actin cytoskeleton
was also corroborated by the fact that a truncated version of the
receptor, lacking the α-actinin binding site, was unable to either
internalize or to cluster upon agonist challenge, an effect that was
reproduced when the actin cytoskeleton was depolymerized by
incubating the cells with cytochalasin D [61]. From here, we can
assume that the α-actinin-mediated A2AR attachment to the actin
cytoskeleton is a prerequisite for the agonist-induced plasma
membrane clustering and β-arrestin-mediated internalization. Over-
all, these data underlie the importance of this physical interaction for
the A2AR trafﬁcking and function.
3.2.2. Arf nucleotide site opener (ARNO)/cytohesin-2
Another conﬁrmed A2AR interacting protein, through the C-
terminal tail at the inner leaﬂet of the plasma membrane, is ARNO
(Arf nucleotide site opener)/cytohesin-2, a nucleotide exchange
factor for the small (monomeric) G proteins of the Arf (ADP-
ribosylation factor) family (Fig. 2) [75]. ARNO/cytohesin-2 is thought
to act as the guanine nucleotide exchange factor of Arf6, a member of
the Arf family required for the internalization of many GPCRs [76] and
distinct from other members of this family because of its location
primarily at the cell membrane (Fig. 2). Here, Arf6 regulates
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well-understood clathrin/caveolae-independent pathway. Interest-
ingly, it was shown that the A2AR-mediated adenylyl cyclase
activation was neither affected by ARNO nor by its dominant-negative
[75]. These results suggest that ARNO/cytohesin-2 is neither involved
in the Gs-mediated cAMP increase induced after A2AR stimulation nor
in the agonist-mediated receptor desensitization mechanism. How-
ever, as previously mentioned, the A2AR can also signal through the
ERK/MAP kinase pathway in a Gs-independent fashion, in which
activation of A2ARs promotes an ERK1/2 biphasic phosphorylation.
Firstly, there is an initial fast and robust phosphorylation, that is next
followed by a swift decline that rapidly rises again, in a slower and
slight phosphorylation with a longer time-span [25]. Interestingly, it
was demonstrated by means of the co-expression of A2AR with an
ARNO dominant-negative mutant, that ARNO/cytohesin-2 was
essential in the A2AR-mediated ERK1/2 phosphorylation second
phase [75]. Consequently, the binding of ARNO/cytohesin-2 to the
proximal portion of the C-terminal tail of the receptor might be a
prerequisite that allows the A2AR to signal in a Gs-independent mode.
Overall, it can be concluded that different mechanisms must be
involved in the A2AR-mediated biphasic phosphorylation of ERK1/2,
which brings a greater diversity regarding the signaling features of
this adenosine receptor subtype and presumably of other GPCRs.
Another fact worth mentioning is that although the C-terminal tail of
the A2AR is relatively long, both α-actinin and ARNO/cytohesin-2
interact with a similar amino acidic region of the receptor: α-actinin
binds speciﬁcally to a region between amino acids 293 and 321 [61],
while ARNO/cytohesin-2 interacts with the region comprised be-
tween amino acids 290 and 311 [75]. Thus, the close vicinity showed
by both interacting molecules opens up the question of the existence
of a ﬁne-tuning regulatory mechanism driving the binding of α-
actinin and ARNO/cytohesin-2 to the C-terminal tail of A2AR. Further
efforts will be needed to ﬁnd out the basis of those regulatory
mechanisms and we envisage that this interacting dichotomy might
be behind the regulation of the actin cytoskeleton remodeling under
certain circumstances. Indeed, ARNO/cytohesin-2 is recruited to the
plasma membrane by ARL4D where it efﬁciently activates Arf6. As a
consequence, Arf6-GTP induces membrane rufﬂing by decreasing the
number of actin stress ﬁbers, thus modulating actin remodeling [77].
On the other hand, α-actinin is necessary for F-actin bundle
formation, hence having the opposite effect than ARNO/cytohesin-2.
Therefore, given that both α-actinin and ARNO/cytohesin-2 proteins
compete for the interaction with the A2AR, it would seem adequate to
prospect if this receptor plays a role in such ﬁne-tuning regulation.
3.2.3. Ubiquitin-speciﬁc protease 4 (USP4)
In a different way from the previously described A2AR-binding
proteins, the ubiquitin-speciﬁc protease 4 (USP4) has been shown to
bind to this receptor within the last 50 amino acids of the C-terminal
tail (Fig. 2) [78], thus it does not compete with α-actinin nor with
ARNO/cytohesin-2 for the C-terminal domain of the receptor.
Ubiquitination plays a key role in the quality control mechanism of
cells and ensures a correct folding of newly synthesized membrane
proteins before they leave the endoplasmic reticulum (ER). Mem-
brane proteins have to be inserted cotranslationally into the
endoplasmic reticulum via the translocon, a channel formed by the
Sec61 subunit [79]. Incorrect folding, detected by chaperons in the ER,
leads to the activation of ubiquitinating enzymes and the consequent
retrotranslocation of the misfolded protein and degradation by the
26S proteasome [80]. Deubiquitinating enzymes are divided into
three different subfamilies: the smaller ubiquitin C-terminal hydro-
lase (UCH) subfamily, the larger ubiquitin-speciﬁc processing prote-
ase (USP/UBP) subfamily and the subfamily of OUT-domain
containing proteins. Thus, USP/UBPs are large proteins and represent
the vast majority of deubiquitinating enzymes [81]. It was Milojevic
and collaborators that identiﬁed the ubiquitin-speciﬁc protease USP4as a protein partner that played a pivotal role in controlling cell
surface trafﬁcking of newly synthesized A2ARs (Fig. 2). In such way,
several evidences for the speciﬁcity of the interaction between USP4
and A2ARs were provided. Namely, when compared to the wild-type
receptor, the overexpression of USP4 failed to promote the cell surface
expression of a C-terminal deleted A2AR version which lacked the
USP4 interacting domain. On the other hand, another protein from the
USP family, namely the USP14, failed to mimic the USP4 effects (e.g. to
rescue A2AR to the cell surface). And ﬁnally, USP4 did not have any
effect on cell surface expression of another GPCR, as the metabotropic
glutamate receptor type 5, thus conﬁrming the speciﬁcity of the A2AR/
USP4 interaction [78]. Collectively, all the existing data indicate that
by its interaction with USP4, the A2AR relaxes its ER quality control,
thus favoring its ER exit and the subsequent plasma membrane
trafﬁcking (Fig. 2). For instance, an increment in the expression of
USP4 may increase the subsequent deubiquitination of A2ARs, thus
leading to an increase in A2AR cell surface expression (Fig. 2).
Interestingly, there are several human pathologies that are the result
of an exaggerated intervention of these ER quality control mechan-
ismswhich are designated to guaranty that misfolded proteins are not
delivered to the cell surface, even in the case where they may still be
functional [80,82]; for instance, such is the case of cystic ﬁbrosis,
typically caused by a mutation on the CFTR transporter [83], and
diabetes insipidus, where there is a defect of the V2-vasopressin
receptor [84]. Thus, in a similar manner, this might have special
relevance in the pathoﬁsiological conditions where A2ARs have been
proved to be involved (e.g. Parkinson's disease), and where its hiper-
or hipofunction might be controlled by the USP4-mediated receptor
cell surface expression.
3.2.4. Translin-associated protein X (TRAX)
TRAX (Translin-associated protein X) is another protein that binds
to the C-terminal tail of the A2AR (Fig. 2). This interaction was
identiﬁed in a yeast two-hybrid screen and later conﬁrmed by pull-
down assays, co-immunoprecipitation and co-localization experi-
ments in the brain [85]. TRAX is a 33-kDa cytoplasmatic protein that
was ﬁrst described as an interacting partner for Translin [86]. Translin
is an RNA and single-stranded DNA-binding protein, involved in DNA
rearrangement and repair, mitotic cell division, mRNA transport and
translational regulation [87]. For instance, one of the TRAX-mediated
effects on Translin consists in reducing the binding afﬁnity for RNA
but not to DNA [88]. The TRAX/Translin protein complexes are located
in centrosomes, where they play an important role in cell cycle control
and proliferation [89], and in neuronal dendrites, where a role in RNA
processing is the most plausible function [90]. TRAX may be
implicated as well in DNA repair via binding to the nuclear matrix
protein, C1D, an activator of the DNA-dependent protein kinase
essential for DNA double-strand repair and V(D)J recombination [91].
Also, it was recently shown that TRAX regulated GAP-43 transcription
and regeneration-promoting effects during the postnatal maturation
period [92]. Nevertheless, very little is known about TRAX biological
functions, even when, in addition, four other TRAX interacting
proteins with a cytosolic location have been described: snaxip1,
MEA-2, Akap9, and Sun-1 [93].
Interestingly, it was recently proved that the ability of A2AR to
regulate proliferation and neurite outgrowth was TRAX-dependent
(Fig. 2) [85]: ﬁrst, a truncated version of the receptor missing its C-
terminal tail, where the potential binding site of TRAX is located,
registered a decline of the rescue effect; and secondly, a markedly
reduction was achieved with the transfection of an antisense
construct of TRAX in PC-12 cells. Moreover, TRAX overexpression in
these cells rescued by itself the reduced neurite outgrowth caused by
a p53 impairment. Overall, under the light of all these evidences, the
interaction between the A2AR and TRAX might represent a new GPCR
signal transduction pathway where extracellular signals are trans-
mitted to the nucleus or to the translational machinery.
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So far, the last protein shown to interact with the C-terminal tail of
the A2AR is NECAB2 (Neuronal Calcium-Binding Protein 2) [94].
NECAB2 belongs to a family of neuronal Ca2+-binding proteins that
share common structural features. Brieﬂy, at the N-terminus, NECAB
proteins contain an EF-hand domain with a single Ca2+-binding site
which is responsible for the calcium binding, thus differing frommany
other neuronal EF-hand Ca2+-binding proteins [95]. Next to the EF-
hand domain, there is a central unique and highly conserved region
also called NHR (NECAB homology region) domain which is
characterized by the presence of a coiled-coil domain. Finally, at the
C-terminal part of the NECAB molecule a DUF176 or ABM motif is
found, a bacterial domain of unknown function in mammalians that
was previously found in monooxygenases involved in the biosynthe-
sis of several antibiotics in Streptomyces species. NECAB's family is
composed by threemembers that are expressed in rat either primarily
in brain (NECAB1 and 2) or in both brain and muscle (NECAB3) [96].
The NECAB protein function still remains largely unknown. Regarding
NECAB1, which is also called EFCBP1, it was isolated using afﬁnity
chromatography on the C2A domain of synaptotagmin 1 (Syt 1) [97].
This subtype of NECAB protein is mainly expressed in the temporal
and fontal lobes, the occipital pole and the putamen in the brain [98],
thus making feasible the potential implication of this protein in the
sensory processing and cognitive functions, although the mechanisms
behind its function remain unravelled. About NECAB3, also called
XB51/NIP1, it was isolated as an interacting partner of the neuron-
speciﬁc X11-like protein (X11L) [99] and it has been suggested that it
may play an important role in the regulatory system of amyloid
precursor protein (APP) metabolism and β-amyloid generation
[99,100]. Also, it has been shown that NECAB3 is a potential substrate
of themammalian protein kinase Nek2, a protein that share homology
with the Aspergillus NIMA kinase which plays a key role in controlling
entrance into mitosis and required for centrosome assembly and
maintenance [101]. Concerning NECAB2, it was demonstrated both
heterologous in systems and in native tissue the existence of a short
isoform, NECAB2S, generated by the presence of an extra putative
translation initiation codon within the cDNA sequence of NECAB2,
thus generating a shorter protein (39 kDa) when compared to the full
length NECAB2 protein (43 kDa) [94,96]. Interestingly, both long and
short isoforms of NECAB2were recently identiﬁed as binding partners
for the C-terminal domain of A2AR [94]. By means of immunoelectron
microscopy detection of NECAB2 and A2AR in the rat striatopallidal
structures, it was shown that both proteins were co-distributed in the
same glutamatergic nerve terminals, thus this interaction might be
physiologically relevant in vivo [94]. Indeed, besides NECAB2 reduced
(∼25%) cell surface expression of A2AR, the agonist-promoted
signaling of the receptor was enhanced (Fig. 2) [94]. In addition,
calcium ions markedly inhibited in a dose-dependent manner the
binding of NECAB2 to A2AR in vitro, suggesting that the degree of
interaction between these two proteins was determined by the
physiological concentration of intracellular calcium ions. Therefore,
signals that raise the intracellular calcium concentration will, in
theory, promote dissociation of NECAB2 from A2AR, thus affecting the
receptor-mediated signal transduction and cell surface expression of
the receptor. NECAB2 and α-actinin share in common the fact that
they interact with A2AR and that they both contain EF-hand domains,
thus making the interaction with A2AR potentially dependent of
intracellular calcium ions. In contrast, they differ in their ability to
modulate cell surface expression of A2AR.
Overall, it is important to mention here that although the A2AR C-
terminal tail may exist in an extended conformation [102], hence
providing room enough for direct protein–protein interactions, the
size of the individual binding partners (see Fig. 2) makes it unlikely
that the C terminus can accommodate several partners simultaneous-
ly. These interactions probably occur in a more subtle way, since the
binding site for some of the interacting molecules is pretty close oreven overlap (e.g. α-actinin and ARNO). Thus, individual interactions
are likely to be only transient, a feature that will allow the A2AR C-
terminal tail to become a signal integrator where interacting proteins
will associate or dissociate depending on cellular inputs.
3.3. Adenosine A2B receptor interacting proteins (A2BRIPs)
The knowledge of A2BRs molecular pharmacology and physiolog-
ical relevance has been always one step behind the other adenosine
receptor subtypes. Several reasons might account for this issue but
classically the lack of selective drugs together with the fact that A2BRs
have lower afﬁnity for adenosine when compared to A1R and A2AR
(Table 1), has led to the false assumption that these receptors are of
lesser physiological relevance [26]. Interestingly, this adenosine
receptor subtype couples to different intracellular pathways from
those described for A2AR, a fact that may account for their distinct
physiological role. Thus, A2BR stimulation leads to an increase in either
cAMP or IP3 levels, so it has been proposed that it can activate both Gs,
through which they couple to calcium channels [26], and Gq proteins
(Table 1). As far as the intracellular pathways are concerned, these
receptors have as much in common with A1R (activation of
phospholipase C) as with A2AR receptors (activation of adenylyl
cyclase).
From the pharmacological point of view, A2BRs have been
historically orphans of selective agonists and its afﬁnity for nonselec-
tive agonists (e.g. 5′-Nethylcarboxamidoadenosine, NECA) is notably
lower when compared to the other adenosine receptors. It was not
until very recently that high afﬁnity agonists and antagonists for A2BR
were developed (for review see [103]). Interestingly, A2BR were
implicated in mast cell activation and asthma, vasodilation, regulation
of cell growth, intestinal function and modulation of neurosecretion
[26]. As a consequence, this subtype of adenosine receptors would
have a broad potential of therapeutic action; in fact, as we speak, some
A2BR agonists are under preclinical scrutiny for potential treatment of
cardiac ischemia [2,104].
Also, when compared with the previously described adenosine
receptor subtypes, the search for A2BR interacting partners has been
always one step behind, thus the use of massive proteomic (e.g. pull-
down or protein–protein afﬁnity chromatography) and genomic (e.g.
yeast two-hybrid screening) experimental approaches has not been
commonly applied in the study of this receptor subtype. Therefore,
only sporadic descriptions of interacting proteins have been shown,
namely adenosine deaminase (ADA), SNARE complex and NHERF-2.
Also, another particular interaction involving A2BR and the deleted
colorectal cancer protein (DCC) has been described, but it have been
met with some controversy. Brieﬂy, DCC, which has been postulated
to be a netrin receptor, was found to be a binding partner of A2BR in a
yeast two-hybrid screen [105]. These authors found that A2BR was a
netrin-1 receptor and induced cAMP accumulation on binding netrin-
1, thus proposing that the growth-promoting function of netrin-1
would require a receptor complex containing DCC and A2BR [105]. On
the other hand, Stein and collaborators demonstrated that DCC, apart
to bind directly netrin-1, played a central role in netrin signaling of
axon growth and guidance and this was independent of A2BR
activation [106]. Thus, the A2BR activation, which was initially
proposed to contribute to netrin effects on axons, was not required
for rat commissural axon outgrowth or Xenopus spinal axon attraction
to netrin-1 [106]. Therefore, the initially described A2BR/DCC
interaction might have not relevance in vivo.
Trafﬁcking of the A2BR involves different processes and interacting
proteins which are necessary for triggering and sustaining receptor
movement, as it is generally described for GPCRs. Interestingly, it was
observed that, in cells with reduced levels of arrestin or when its
expression was depleted, endogenous A2BR resensitization was
affected, while overexpression of either arrestin-2 or arrestin-3
reversed this impairment. Furthermore, agonist activation of A2BRs
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and subsequently after long agonist treatment both proteins, A2AR
and arrestin-2GFP, underwent internalization to compartments which
co-localized with the endosomal markers transferrin and rab-5 [107].
Also, it was demonstrated that the A2BR internalized in an arrestin-
and dynamin-sensitive fashion [108]. It has been extensively
described that arrestins bind to GPCRs upon GRK-mediated receptor
phosphorylation [109]; for A2BR, it was described that GRK2 was the
kinase involved in the process [110] and a serine residue (Ser329) close
to the end of the COOH terminus of A2BR was critical for rapid agonist-
induced desensitization and internalization of the receptor [111].
Overall, it is generally accepted that A2BR undergoes desensitization
and internalization in a GRK- and arrestin-dependent manner.
Interestingly, it was demonstrated that after transient (5 min) A2BR
agonist challenge the receptor co-immunoprecipitated as part of a
multiprotein complex containing SNAP-23 and VAMP-2 [112]. In
polarized epithelial cells, it was proposed that under resting
conditions A2BR accumulated in intracellular compartments, thus
after apical or basolateral agonist challenge the receptor was recruited
to the apical membrane where the SNARE proteins, VAMP-2 and
SNAP-23, were in charge of this recruitment, therefore the SNARE-
mediated A2BR-plasma membrane recruitment might be required for
receptor signaling (Fig. 3) [112].
Once the receptor is recruited to the plasma membrane by the
SNARE proteins, then it is anchored there with its signaling complex
via its interaction with NHERF-2 and ezrin proteins (Fig. 3) [113].
Ezrin is known to act as a protein kinase A (PKA) anchoring protein
[114] in addition to associate with the actin cytoskeleton (Fig. 3)Fig.3. Schematic representation of A2BR interaction with ADA, NHERF-2 and SNARE protein
NHERF-2 with the intracellular domains of the receptor. Ezrin (PDB ID: 1ni2), NHERF-2 (PDB
are prepared has described in Fig. 1.(reviewed in [115]). The interaction between NHERF, ezrin, and PKA
has been shown to be critical for the functional response of
transporters including CFTR [114] and NHE-3 [116]. Interestingly, it
was shown that A2BR co-immunoprecipitated with both ezrin and
NHERF-2 proteins [113], a fact that seemed to indicate that this
complexwould act as a stabilizing scaffold thatmay enhance signaling
after the receptor is stimulated.
As it has been described for A1R, adenosine deaminase (ADA) also
interacts with the A2BR subtype. ADA has been shown to be expressed
in the surface of lymphocytes where it interacts with the T-cell
activation antigen CD26. Interestingly, the interaction of ADA with
A2BR in CHO and Jurkat cells, an immortalized line of T lymphocyte
cells, increased the afﬁnity of the receptor for the non-selective
agonist NECA and also potentiated receptor-mediated cAMP produc-
tion [117]. Therefore, cell surface ADA, apart from degrading
extracellular adenosine, would regulate the adenosine actions that
are mediated via A2BR subtype, in lymphocytes. Finally, the interac-
tion between A2BR and the enzyme was also observed in cultured
dendritic cells [118]. Dendritic cells are the most potent antigen-
presenting cells (APC) specialized in the initiation of immune
responses by directing the activation and differentiation of naïve T
lymphocytes [119]. In this context, ADA anchored to the surface of
dendritic cells by means of an A2BR-mediated attachment would
interact with the CD26which is expressed on the surface of the T cells,
thus triggering costimulation. This costimulatory signal would
promote an augmented T cell activation with a Th1 pattern and
proinﬂammatory cytokine production, therefore enabling an en-
hanced immune response [118].s. Proposed interacting model where ADA interacts with the extracellular domain and
ID: 2ocs), PKA (PDB ID: 2uzt), SNARE complex (PDB ID: 1kil). The schematic diagrams
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The A3R was the last adenosine receptor subtype cloned [120], and
it was quickly demonstrated that this adenosine receptor subtype
inhibited cAMP accumulation after agonist challenge [121]. Therefore,
A3R is coupled to Gi2,3 and Gq/11 proteins, leading to adenylyl cyclase
inhibition and stimulation of phospholipase C (PLC), thus reducing
cAMP levels and increasing IP3, intracellular calcium and DAG
(Table 1). These main signaling pathways, together with other
secondary routes, regulate several functions, such as neuroprotection
and neurodegeneration, cardioprotection, inﬂammatory signals,
immunostimulation and tumorigenic effects [122]. For instance,
adenosine released during cardiac ischemia exerts a potent, protective
effect in the heart, an effect that might be mediated via the activation
of A3R, which is expressed on cardiac ventricular cells. Furthermore,
A3R has been shown to be involved in the inhibition of neutrophil
degranulation in neutrophil-mediated tissue injury. Also, it has both
neuroprotective and neurodegenerative effects, and it may also
mediate both cell proliferation and cell death. In consequence, given
that the A3R has emerged as a new adenosine-based therapeutic
target, the pharmacology around this receptor has quickly grown; for
instance, the A3R selective agonist CP-532,903 has been shown to
protect against myocardial ischemia and reperfusion injury in a
mouse model of infarction [123], and CF-101, also an A3R agonist, is in
clinical trials for the treatment of rheumatoid arthritis [124]. Overall,
nowadays it can be speculated that A3R receptor selective ligands
might show utility in the treatment of ischemic conditions, glaucoma,
asthma, arthritis, cancer and other disorders in which inﬂammation is
a feature [122].
It is important to mention here that when compared with the
other adenosine receptor subtype members in general and with A1R
and A2AR in particular, the A3R does not have any speciﬁc protein
described to interact with, apart from the hypothesized for GPCRs
functioning (e.g. G proteins, etc.). Thus, it was shown that GRK2 was
involved in the receptor desensitization, although no direct interac-
tionwas proven [125]. Furthermore, this trafﬁcking did not seem to be
mediated by arrestins, since they did not co-localize with A3R upon
agonist stimulation in neither RBL-2H3 nor CHO cell lines [126,127].
Thus, when compared to the other three adenosine receptor subtypes
very little is known about the surrounding A3R multiprotein
environment which might be critical to understand the receptor
function under normal and pathological conditions. Therefore, more
work providing information about A3R interacting partners is needed.
4. Concluding remarks
GPCRs in general, and adenosine receptors in particular, have been
shown to interact with a large array of accessory proteins different
from receptors that in one way or another impinge into receptor
function. The ARIPs described here have been discovered by means of
genomic and proteomic approaches and validated by using typical
biochemical and also ﬂuorescence-based methods (e.g. ﬂuorescence/
bioluminescence resonance energy transfer approaches). Surprising-
ly, despite of the relatively small extracellular/intracellular receptor
domains, they have been shown to interact proliﬁcally with a large
number and variety of proteins. Therefore, one would expect that
these interactions, some of them targeting the same receptor domain,
should be regulated in a subtle way in order to allow a ﬁne-tune
modulation of receptor function. Now, the challenge would be to
functionally/molecularly characterize these interactions in native
tissue and to determine how they orchestrate to regulate receptor
functioning. At this point, several issues should be taken into account
to fully understand the role of these interactions in both normal and
pathological conditions: the differential spatio-temporal expression
pattern of each independent protein versus the receptor involved, the
stoichiometry and relative afﬁnity of these accessory proteins for thereceptors, and the functional and molecular cross-talk between the
different ARIPs. Overall, the in vivo know-how of these issues will be
mandatory before the design of any tentative adenosine receptor
interactome-based therapeutic strategy.Acknowledgements
This work was supported by grants SAF2008-01462 and Con-
solider-Ingenio CSD2008-00005 from Ministerio de Ciencia e Innova-
ción. The authors belong to the “Neuropharmacology and Pain”
accredited research group (Generalitat de Catalunya, 2009 SGR 232).References
[1] A.N. Drury, A. Szent-Gyorgyi, The physiological activity of adenine compounds
with especial reference to their action upon the mammalian heart, J. Physiol. 68
(1929) 213–237.
[2] K.A. Jacobson, Z.G. Gao, Adenosine receptors as therapeutic targets, Nat. Rev.,
Drug Discov. 5 (2006) 247–264.
[3] M.P. Abbracchio, G. Burnstock, A. Verkhratsky, H. Zimmermann, Purinergic
signalling in the nervous system: an overview, Trends Neurosci. 32 (2009)
19–29.
[4] A.C. Newby, Adenosine and the concept of “retaliatory metabolites”, Trends
Biochem. Sci. 9 (1984) 42–44.
[5] I. Pull, H. McIlwain, Adenine derivatives as neurohumoral agents in the brain.
The quantities liberated on excitation of superfused cerebral tissues, Biochem. J.
130 (1972) 975–981.
[6] A. Sattin, T.W. Rall, The effect of adenosine and adenine nucleotides on the cyclic
adenosine 3′, 5′-phosphate content of guinea pig cerebral cortex slices, Mol.
Pharmacol. 6 (1970) 13–23.
[7] T. Degubareff, W. Sleator Jr., Effects of caffeine on mammalian atrial muscle, and
its interaction with adenosine and calcium, J. Pharmacol. Exp. Ther. 148 (1965)
202–214.
[8] T. Trost, K. Stock, Effects of adenosine derivatives on cAMP accumulation and
lipolysis in rat adipocytes and on adenylate cyclase in adipocyte plasma
membranes, Naunyn Schmiedebergs Arch. Pharmacol. 299 (1977) 33–40.
[9] C. Londos, D.M. Cooper, J. Wolff, Subclasses of external adenosine receptors, Proc.
Natl. Acad. Sci. U. S. A. 77 (1980) 2551–2554.
[10] D. van Calker, M. Muller, B. Hamprecht, Adenosine regulates via two different
types of receptors, the accumulation of cyclic AMP in cultured brain cells, J.
Neurochem. 33 (1979) 999–1005.
[11] A.M. Sebastiao, J.A. Ribeiro, Fine-tuning neuromodulation by adenosine, Trends
Pharmacol. Sci. 21 (2000) 341–346.
[12] S. Latini, F. Pedata, Adenosine in the central nervous system: releasemechanisms
and extracellular concentrations, J. Neurochem. 79 (2001) 463–484.
[13] S.H. Snyder, Adenosine as a neuromodulator, Annu. Rev. Neurosci. 8 (1985)
103–124.
[14] S. Ferre, K. Fuxe, Adenosine as a volume transmission signal. A feedback detector
of neuronal activation, Prog. Brain Res. 125 (2000) 353–361.
[15] B.B. Fredholm, Purinoceptors in the nervous system, Pharmacol. Toxicol. 76
(1995) 228–239.
[16] M.E. Olah, G.L. Stiles, Adenosine receptor subtypes: characterization and
therapeutic regulation, Annu. Rev. Pharmacol. Toxicol. 35 (1995) 581–606.
[17] J. Bockaert, J.P. Pin, Molecular tinkering of G protein-coupled receptors: an
evolutionary success, EMBO J. 18 (1999) 1723–1729.
[18] R. Fredriksson, M.C. Lagerstrom, L.G. Lundin, H.B. Schioth, The G-protein-coupled
receptors in the human genome form ﬁve main families. Phylogenetic analysis,
paralogon groups, and ﬁngerprints, Mol. Pharmacol. 63 (2003) 1256–1272.
[19] L.F. Kolakowski Jr., GCRDb: a G-protein-coupled receptor database, Recept.
Channels 2 (1994) 1–7.
[20] O. Fritze, S. Filipek, V. Kuksa, K. Palczewski, K.P. Hofmann, O.P. Ernst, Role of the
conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during
activation, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 2290–2295.
[21] G.E. Rovati, V. Capra, R.R. Neubig, The highly conserved DRY motif of class A G
protein-coupled receptors: beyond the ground state, Mol. Pharmacol. 71 (2007)
959–964.
[22] T.V. Dunwiddie, S.A. Masino, The role and regulation of adenosine in the central
nervous system, Annu. Rev. Neurosci. 24 (2001) 31–55.
[23] T.M. Palmer, G.L. Stiles, Adenosine receptors, Neuropharmacology 34 (1995)
683–694.
[24] R.B. Marala, S.J. Mustafa, Direct evidence for the coupling of A2-adenosine
receptor to stimulatory guanine nucleotide-binding-protein in bovine brain
striatum, J. Pharmacol. Exp. Ther. 266 (1993) 294–300.
[25] S. Ferre, M. Karcz-Kubicha, B.T. Hope, P. Popoli, J. Burgueno, M.A. Gutierrez, V.
Casado, K. Fuxe, S.R. Goldberg, C. Lluis, R. Franco, F. Ciruela, Synergistic
interaction between adenosine A2A and glutamate mGlu5 receptors: implica-
tions for striatal neuronal function, Proc. Natl. Acad. Sci. U. S. A. 99 (2002)
11940–11945.
[26] I. Feoktistov, I. Biaggioni, Adenosine A2B receptors, Pharmacol. Rev. 49 (1997)
381–402.
19F. Ciruela et al. / Biochimica et Biophysica Acta 1798 (2010) 9–20[27] F. Ciruela, R. Lujan, Molecular Aspects of G Protein-Coupled Receptors:
Interacting Proteins and Function, Nova Science Publishers, Inc., Hauppauge,
New York, USA., 2007
[28] M. Kimura, N. Saitoh, T. Takahashi, Adenosine A(1) receptor-mediated
presynaptic inhibition at the calyx of Held of immature rats, J. Physiol. 553
(2003) 415–426.
[29] K.A. Moore, R.A. Nicoll, D. Schmitz, Adenosine gates synaptic plasticity at
hippocampal mossy ﬁber synapses, Proc. Natl. Acad. Sci. U. S. A. 100 (2003)
14397–14402.
[30] C. Lluis, R. Franco, O. Cordero, Ecto-ADA in the development of the immune
system, Immunol. Today 19 (1998) 533–534.
[31] R. Franco, V. Casado, F. Ciruela, C. Saura, J. Mallol, E.I. Canela, C. Lluis, Cell surface
adenosine deaminase: much more than an ectoenzyme, Prog. Neurobiol. 52
(1997) 283–294.
[32] F. Ciruela, C. Saura, E.I. Canela, J. Mallol, C. Lluis, R. Franco, Adenosine deaminase
affects ligand-induced signalling by interacting with cell surface adenosine
receptors, FEBS Lett. 380 (1996) 219–223.
[33] C. Saura, F. Ciruela, V. Casado, E.I. Canela, J. Mallol, C. Lluis, R. Franco, Adenosine
deaminase interacts with A1 adenosine receptors in pig brain cortical
membranes, J. Neurochem. 66 (1996) 1675–1682.
[34] M.A. Ruiz, M. Escriche, C. Lluis, R. Franco, M. Martin, A. Andres, M. Ros, Adenosine
A(1) receptor in cultured neurons from rat cerebral cortex: colocalization with
adenosine deaminase, J. Neurochem. 75 (2000) 656–664.
[35] M. Torvinen, S. Gines, J. Hillion, S. Latini, M. Canals, F. Ciruela, F. Bordoni, W.
Staines, F. Pedata, L.F. Agnati, C. Lluis, R. Franco, S. Ferre, K. Fuxe, Interactions
among adenosine deaminase, adenosine A(1) receptors and dopamine D(1)
receptors in stably cotransfected ﬁbroblast cells and neurons, Neuroscience 113
(2002) 709–719.
[36] E. Gracia, A. Cortes, J.J. Meana, J. Garcia-Sevilla, M.S. Herhsﬁeld, E.I. Canela, J.
Mallol, C. Lluis, R. Franco, V. Casado, Human adenosine deaminase as an allosteric
modulator of human A(1) adenosine receptor: abolishment of negative
cooperativity for [H](R)-pia binding to the caudate nucleus, J. Neurochem. 107
(2008) 161–170.
[37] C.A. Saura, J. Mallol, E.I. Canela, C. Lluis, R. Franco, Adenosine deaminase and A1
adenosine receptors internalize together following agonist-induced receptor
desensitization, J. Biol. Chem. 273 (1998) 17610–17617.
[38] Z. Li, P. Srivastava, Heat-shock proteins, Curr. Protoc. Immunol. Appen. 1 (2004)
Appendix 1T.
[39] S. Sarrio, V. Casado, M. Escriche, F. Ciruela, J. Mallol, E.I. Canela, C. Lluis, R. Franco,
The heat shock cognate protein hsc73 assembles with A(1) adenosine receptors
to form functional modules in the cell membrane, Mol. Cell. Biol. 20 (2000)
5164–5174.
[40] N.J. Severs, Caveolae: static inpocketings of the plasma membrane, dynamic
vesicles or plain artifact? J. Cell. Sci. 90 (Pt. 3) (1988) 341–348.
[41] R.G. Parton, K. Simons, The multiple faces of caveolae, Nat. Rev., Mol. Cell Biol.
8 (2007) 185–194.
[42] H.H. Patel, F. Murray, P.A. Insel, Caveolae as organizers of pharmacologically
relevant signal transduction molecules, Annu. Rev. Pharmacol. Toxicol. 48
(2008) 359–391.
[43] Z. Tang, P.E. Scherer, T. Okamoto, K. Song, C. Chu, D.S. Kohtz, I. Nishimoto, H.F.
Lodish, M.P. Lisanti, Molecular cloning of caveolin-3, a novel member of the
caveolin gene family expressed predominantly in muscle, J. Biol. Chem. 271
(1996) 2255–2261.
[44] M. Murata, J. Peranen, R. Schreiner, F. Wieland, T.V. Kurzchalia, K. Simons, VIP21/
caveolin is a cholesterol-binding protein, Proc. Natl. Acad. Sci. U. S. A. 92 (1995)
10339–10343.
[45] D.J. Dietzen, W.R. Hastings, D.M. Lublin, Caveolin is palmitoylated on multiple
cysteine residues. Palmitoylation is not necessary for localization of caveolin to
caveolae, J. Biol. Chem. 270 (1995) 6838–6842.
[46] K.G. Rothberg, J.E. Heuser, W.C. Donzell, Y.S. Ying, J.R. Glenney, R.G. Anderson,
Caveolin, a protein component of caveolaemembrane coats, Cell 68 (1992) 673–682.
[47] J.A. Allen, J.Z. Yu, R.J. Donati, M.M. Rasenick, Beta-adrenergic receptor stimulation
promotes G alpha s internalization through lipid rafts: a study in living cells, Mol.
Pharmacol. 67 (2005) 1493–1504.
[48] S. Gines, F. Ciruela, J. Burgueno, V. Casado, E.I. Canela, J. Mallol, C. Lluis, R. Franco,
Involvement of caveolin in ligand-induced recruitment and internalization of A
(1) adenosine receptor and adenosine deaminase in an epithelial cell line, Mol.
Pharmacol. 59 (2001) 1314–1323.
[49] M. Escriche, J. Burgueno, F. Ciruela, E.I. Canela, J. Mallol, C. Enrich, C. Lluis, R.
Franco, Ligand-induced caveolae-mediated internalization of A1 adenosine
receptors: morphological evidence of endosomal sorting and receptor recycling,
Exp. Cell Res. 285 (2003) 72–90.
[50] K.B. Hoover, P.J. Bryant, The genetics of the protein 4.1 family: organizers of the
membrane and cytoskeleton, Curr. Opin. Cell Biol. 12 (2000) 229–234.
[51] D. Lu, H. Yan, T. Othman, C.P. Turner, T. Woolf, S.A. Rivkees, Cytoskeletal protein
4.1G binds to the third intracellular loop of the A1 adenosine receptor and
inhibits receptor action, Biochem. J. 377 (2004) 51–59.
[52] N. Ohno, N. Terada, J. Tanaka, A. Yokoyama, H. Yamakawa, Y. Fujii, T. Baba, O.
Ohara, S. Ohno, Protein 4.1 G localizes in rodent microglia, Histochem. Cell Biol.
124 (2005) 477–486.
[53] A.M. Sebastiao, J.A. Ribeiro, Adenosine A2 receptor-mediated excitatory actions
on the nervous system, Prog. Neurobiol. 48 (1996) 167–189.
[54] D.K. von Lubitz, Adenosine and cerebral ischemia: therapeutic future or death of
a brave concept? Eur. J. Pharmacol. 371 (1999) 85–102.
[55] N. Rebola, R.J. Rodrigues, L.V. Lopes, P.J. Richardson, C.R. Oliveira, R.A. Cunha,
Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus, Neuroscience
133 (2005) 79–83.
[56] F. Ciruela, V. Casado, R.J. Rodrigues, R. Lujan, J. Burgueno, M. Canals, J. Borycz, N.
Rebola, S.R. Goldberg, J. Mallol, A. Cortes, E.I. Canela, J.F. Lopez-Gimenez, G.
Milligan, C. Lluis, R.A. Cunha, S. Ferre, R. Franco, Presynaptic control of striatal
glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers, J.
Neurosci. 26 (2006) 2080–2087.
[57] L.V. Lopes, R.A. Cunha, J.A. Ribeiro, Cross talk between A(1) and A(2A) adenosine
receptors in the hippocampus and cortex of young adult and old rats, J.
Neurophysiol. 82 (1999) 3196–3203.
[58] L.V. Lopes, R.A. Cunha, B. Kull, B.B. Fredholm, J.A. Ribeiro, Adenosine A(2A)
receptor facilitation of hippocampal synaptic transmission is dependent on tonic
A(1) receptor inhibition, Neuroscience 112 (2002) 319–329.
[59] F. Ciruela, S. Ferre, V. Casado, A. Cortes, R.A. Cunha, C. Lluis, R. Franco,
Heterodimeric adenosine receptors: a device to regulate neurotransmitter
release, Cell. Mol. Life Sci. 63 (2006) 2427–2431.
[60] C. Missale, S.R. Nash, S.W. Robinson, M. Jaber, M.G. Caron, Dopamine receptors:
from structure to function, Physiol. Rev. 78 (1998) 189–225.
[61] J. Burgueno, D.J. Blake, M.A. Benson, C.L. Tinsley, C.T. Esapa, E.I. Canela, P. Penela,
J. Mallol, F. Mayor Jr., C. Lluis, R. Franco, F. Ciruela, The adenosine A2A receptor
interacts with the actin-binding protein alpha-actinin, J. Biol. Chem. 278 (2003)
37545–37552.
[62] K. Maruyama, S. Ebashi, Alpha-actinin, a new structural protein from striated
muscle. II. Action on actin, J. Biochem. 58 (1965) 13–19.
[63] B. Sjoblom, A. Salmazo, K. Djinovic-Carugo, Alpha-actinin structure and
regulation, Cell. Mol. Life Sci. 65 (2008) 2688–2701.
[64] C.A. Otey, O. Carpen, Alpha-actinin revisited: a fresh look at an old player, Cell
Motil. Cytoskelet. 58 (2004) 104–111.
[65] F. Landon, Y. Gache, H. Touitou, A. Olomucki, Properties of two isoforms of
human blood platelet alpha-actinin, Eur. J. Biochem. 153 (1985) 231–237.
[66] K. Djinovic-Carugo, M. Gautel, J. Ylanne, P. Young, The spectrin repeat: a
structural platform for cytoskeletal protein assemblies, FEBS Lett. 513 (2002)
119–123.
[67] D. Cukovic, G.W. Lu, B. Wible, D.F. Steele, D. Fedida, A discrete amino terminal
domain of Kv1.5 and Kv1.4 potassium channels interacts with the spectrin
repeats of alpha-actinin-2, FEBS Lett. 498 (2001) 87–92.
[68] M. Kim, L.H. Jiang, H.L. Wilson, R.A. North, A. Surprenant, Proteomic and
functional evidence for a P2X7 receptor signalling complex, EMBO J. 20 (2001)
6347–6358.
[69] A.W. Dunah, M. Wyszynski, D.M. Martin, M. Sheng, D.G. Standaert, Alpha-
actinin-2 in rat striatum: localization and interaction with NMDA glutamate
receptor subunits, Brain Res. Mol. Brain Res. 79 (2000) 77–87.
[70] A. Sadeghi, A.D. Doyle, B.D. Johnson, Regulation of the cardiac L-type Ca2+
channel by the actin-binding proteins alpha-actinin and dystrophin, Am. J.
Physiol., Cell., Physiol. 282 (2002) C1502–1511.
[71] Q. Li, N. Montalbetti, P.Y. Shen, X.Q. Dai, C.I. Cheeseman, E. Karpinski, G. Wu, H.F.
Cantiello, X.Z. Chen, Alpha-actinin associates with polycystin-2 and regulates its
channel activity, Hum. Mol. Genet. 14 (2005) 1587–1603.
[72] N. Cabello, R. Remelli, L. Canela, A. Soriguera, J. Mallol, E.I. Canela, M.J. Robbins, C.
Lluis, R. Franco, R.A. McIlhinney, F. Ciruela, Actin-binding protein alpha-actinin-1
interacts with the metabotropic glutamate receptor type 5b and modulates the
cell surface expression and function of the receptor, J. Biol. Chem. 282 (2007)
12143–12153.
[73] B.K. Rycroft, A.J. Gibb, Regulation of single NMDA receptor channel activity by
alpha-actinin and calmodulin in rat hippocampal granule cells, J. Physiol. 557
(2004) 795–808.
[74] K.Wirkner, H. Assmann, L. Koles, Z. Gerevich, H. Franke,W. Norenberg, R. Boehm,
P. Illes, Inhibition by adenosine A(2A) receptors of NMDA but not AMPA currents
in rat neostriatal neurons, Br. J. Pharmacol. 130 (2000) 259–269.
[75] I. Gsandtner, C. Charalambous, E. Stefan, E. Ogris, M. Freissmuth, J. Zezula,
Heterotrimeric G protein-independent signaling of a G protein-coupled receptor.
Direct binding of ARNO/cytohesin-2 to the carboxyl terminus of the A2A
adenosine receptor is necessary for sustained activation of the ERK/MAP kinase
pathway, J. Biol. Chem. 280 (2005) 31898–31905.
[76] T. Houndolo, P.L. Boulay, A. Claing, G protein-coupled receptor endocytosis in
ADP-ribosylation factor 6-depleted cells, J. Biol. Chem. 280 (2005) 5598–5604.
[77] C.C. Li, T.C. Chiang, T.S.Wu, G. Pacheco-Rodriguez, J. Moss, F.J. Lee, ARL4D recruits
cytohesin-2/ARNO to modulate actin remodeling, Mol. Biol. Cell 18 (2007)
4420–4437.
[78] T. Milojevic, V. Reiterer, E. Stefan, V.M. Korkhov, M.M. Dorostkar, E. Ducza, E.
Ogris, S. Boehm, M. Freissmuth, C. Nanoff, The ubiquitin-speciﬁc protease Usp4
regulates the cell surface level of the A2A receptor, Mol. Pharmacol. 69 (2006)
1083–1094.
[79] K. Mitra, J. Frank, A. Driessen, Co- and post-translational translocation through
the protein-conducting channel: analogous mechanisms at work? Nat. Struct.
Mol. Biol. 13 (2006) 957–964.
[80] Z. Kostova, D.H. Wolf, For whom the bell tolls: protein quality control of the
endoplasmic reticulum and the ubiquitin-proteasome connection, EMBO J. 22
(2003) 2309–2317.
[81] S.M. Nijman, M.P. Luna-Vargas, A. Velds, T.R. Brummelkamp, A.M. Dirac, T.K.
Sixma, R. Bernards, A genomic and functional inventory of deubiquitinating
enzymes, Cell 123 (2005) 773–786.
[82] Y. Ye, Y. Shibata, M. Kikkert, S. van Voorden, E. Wiertz, T.A. Rapoport, Inaugural
article: recruitment of the p97 ATPase and ubiquitin ligases to the site of
retrotranslocation at the endoplasmic reticulummembrane, Proc. Natl. Acad. Sci.
U. S. A. 102 (2005) 14132–14138.
20 F. Ciruela et al. / Biochimica et Biophysica Acta 1798 (2010) 9–20[83] R.K. Rowntree, A. Harris, The phenotypic consequences of CFTR mutations, Ann.
Hum. Genet. 67 (2003) 471–485.
[84] A. Oksche, W. Rosenthal, The molecular basis of nephrogenic diabetes insipidus,
J. Mol. Med. 76 (1998) 326–337.
[85] C.N. Sun, H.C. Cheng, J.L. Chou, S.Y. Lee, Y.W. Lin, H.L. Lai, H.M. Chen, Y. Chern,
Rescue of p53 blockage by the A(2A) adenosine receptor via a novel interacting
protein, translin-associated protein X, Mol. Pharmacol. 70 (2006) 454–466.
[86] K. Aoki, R. Ishida, M. Kasai, Isolation and characterization of a cDNA encoding a
Translin-like protein, TRAX, FEBS Lett. 401 (1997) 109–112.
[87] M. Claussen, R. Koch, Z.Y. Jin, B. Suter, Functional characterization of Drosophila
Translin and Trax, Genetics 174 (2006) 1337–1347.
[88] V.M. Chennathukuzhi, Y. Kurihara, J.D. Bray, N.B. Hecht, Trax (translin-associated
factor X), a primarily cytoplasmic protein, inhibits the binding of TB-RBP
(translin) to RNA, J. Biol. Chem. 276 (2001) 13256–13263.
[89] R. Ishida, H. Okado, H. Sato, C. Shionoiri, K. Aoki, M. Kasai, A role for the octameric
ring protein, Translin, in mitotic cell division, FEBS Lett. 525 (2002) 105–110.
[90] P.M. Finkenstadt, W.S. Kang, M. Jeon, E. Taira, W. Tang, J.M. Baraban,
Somatodendritic localization of Translin, a component of the Translin/Trax
RNA binding complex, J. Neurochem. 75 (2000) 1754–1762.
[91] T. Erdemir, B. Bilican, D. Oncel, C.R. Goding, U. Yavuzer, DNA damage-dependent
interaction of the nuclear matrix protein C1D with Translin-associated factor X
(TRAX), J. Cell. Sci. 115 (2002) 207–216.
[92] U. Schroer, G.F. Volk, T. Liedtke, S. Thanos, Translin-associated factor-X (Trax) is a
molecular switch of growth-associated protein (GAP)-43 that controls axonal
regeneration, Eur. J. Neurosci. 26 (2007) 2169–2178.
[93] J.D. Bray, V.M. Chennathukuzhi, N.B. Hecht, Identiﬁcation and characterization of
cDNAs encoding four novel proteins that interact with translin associated factor-
X, Genomics 79 (2002) 799–808.
[94] L. Canela, R. Lujan, C. Lluis, J. Burgueno, J. Mallol, E.I. Canela, R. Franco, F. Ciruela,
The neuronal Ca(2+)-binding protein 2 (NECAB2) interacts with the adenosine
A(2A) receptor and modulates the cell surface expression and function of the
receptor, Mol. Cell. Neurosci. 36 (2007) 1–12.
[95] R.D. Burgoyne, D.W. O'Callaghan, B. Hasdemir, L.P. Haynes, A.V. Tepikin,
Neuronal Ca2+-sensor proteins: multitalented regulators of neuronal function,
Trends Neurosci. 27 (2004) 203–209.
[96] S. Sugita, A. Ho, T.C. Sudhof, NECABs: a family of neuronal Ca(2+)-binding
proteins with an unusual domain structure and a restricted expression pattern,
Neuroscience 112 (2002) 51–63.
[97] S. Sugita, T.C. Sudhof, Speciﬁcity of Ca2+-dependent protein interactionsmediated
by the C2A domains of synaptotagmins, Biochemistry 39 (2000) 2940–2949.
[98] H. Wu, D. Li, Y. Shan, B. Wan, S. Hexige, J. Guo, C. Wu, L. Yu, EFCBP1/NECAB1, a
brain-speciﬁcally expressed gene with highest abundance in temporal lobe,
encodes a protein containing EF-hand and antibiotic biosynthesis monoox-
ygenase domains, DNA Seq. 18 (2007) 73–79.
[99] D.S. Lee, S. Tomita, Y. Kirino, T. Suzuki, Regulation of X11L-dependent amyloid
precursor protein metabolism by XB51, a novel X11L-binding protein, J. Biol.
Chem. 275 (2000) 23134–23138.
[100] A. Sumioka, S. Imoto, R.N. Martins, Y. Kirino, T. Suzuki, XB51 isoforms mediate
Alzheimer's beta-amyloid peptide production by X11L (X11-like protein)-
dependent and -independent mechanisms, Biochem. J. 374 (2003) 261–268.
[101] J.C. Yoo, J.R. Chang, S.H. Kim, S.K. Jang, D.J. Wolgemuth, K. Kim, K. Rhee, NIP1/
XB51/NECAB3 is a potential substrate of Nek2, suggesting speciﬁc roles of Nek2
in Golgi, Exp. Cell Res. 292 (2004) 393–402.
[102] J. Zezula, M. Freissmuth, The A(2A)-adenosine receptor: a GPCR with unique
features, Br. J. Pharmacol. 153 (Suppl. 1) (2008) S184–190.
[103] M.W. Beukers, I. Meurs, A.P. Ijzerman, Structure–afﬁnity relationships of
adenosine A2B receptor ligands, Med. Res. Rev. 26 (2006) 667–698.
[104] Z.G. Gao, K.A. Jacobson, Emerging adenosine receptor agonists, Expert Opin.
Emerg. Drugs 12 (2007) 479–492.
[105] V. Corset, K.T. Nguyen-Ba-Charvet, C. Forcet, E. Moyse, A. Chedotal, P. Mehlen,
Netrin-1-mediated axon outgrowth and cAMP production requires interaction
with adenosine A2b receptor, Nature 407 (2000) 747–750.
[106] E. Stein, Y. Zou, M. Poo, M. Tessier-Lavigne, Binding of DCC by netrin-1 tomediate
axon guidance independent of adenosine A2B receptor activation, Science 291
(2001) 1976–1982.
[107] S.J. Mundell, A.L. Matharu, E. Kelly, J.L. Benovic, Arrestin isoforms dictate
differential kinetics of A2B adenosine receptor trafﬁcking, Biochemistry 39
(2000) 12828–12836.
[108] A. Claing, S.J. Perry, M. Achiriloaie, J.K. Walker, J.P. Albanesi, R.J. Lefkowitz, R.T.
Premont, Multiple endocytic pathways of G protein-coupled receptors delineat-
ed by GIT1 sensitivity, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 1119–1124.[109] R.T. Premont, R.R. Gainetdinov, Physiological roles of G protein-coupled receptor
kinases and arrestins, Annu. Rev. Physiol. 69 (2007) 511–534.
[110] S.J. Mundell, J.S. Luty, J. Willets, J.L. Benovic, E. Kelly, Enhanced expression of G
protein-coupled receptor kinase 2 selectively increases the sensitivity of A2A
adenosine receptors to agonist-induced desensitization, Br. J. Pharmacol. 125
(1998) 347–356.
[111] A.L. Matharu, S.J. Mundell, J.L. Benovic, E. Kelly, Rapid agonist-induced desensiti-
zation and internalization of the A(2B) adenosine receptor is mediated by a serine
residue close to the COOH terminus, J. Biol. Chem. 276 (2001) 30199–30207.
[112] L. Wang, V. Kolachala, B. Walia, S. Balasubramanian, R.A. Hall, D. Merlin, S.V.
Sitaraman, Agonist-induced polarized trafﬁcking and surface expression of the
adenosine 2b receptor in intestinal epithelial cells: role of SNARE proteins, Am. J.
Physiol., Gastrointest. Liver Physiol. 287 (2004) G1100–1107.
[113] S.V. Sitaraman, L.Wang, M.Wong, M. Bruewer, M. Hobert, C.H. Yun, D. Merlin, J.L.
Madara, The adenosine 2b receptor is recruited to the plasma membrane and
associates with E3KARP and Ezrin upon agonist stimulation, J. Biol. Chem. 277
(2002) 33188–33195.
[114] F. Sun, M.J. Hug, C.M. Lewarchik, C.H. Yun, N.A. Bradbury, R.A. Frizzell, E3KARP
mediates the association of ezrin and protein kinase A with the cystic ﬁbrosis
transmembrane conductance regulator in airway cells, J. Biol. Chem. 275 (2000)
29539–29546.
[115] A. Bretscher, D. Chambers, R. Nguyen, D. Reczek, ERM-Merlin and EBP50 protein
families in plasma membrane organization and function, Annu. Rev. Cell Dev.
Biol. 16 (2000) 113–143.
[116] C.H. Yun, G. Lamprecht, D.V. Forster, A. Sidor, NHE3 kinase A regulatory protein
E3KARP binds the epithelial brush border Na+/H+ exchanger NHE3 and the
cytoskeletal protein ezrin, J. Biol. Chem. 273 (1998) 25856–25863.
[117] C. Herrera, V. Casado, F. Ciruela, P. Schoﬁeld, J. Mallol, C. Lluis, R. Franco,
Adenosine A2B receptors behave as an alternative anchoring protein for cell
surface adenosine deaminase in lymphocytes and cultured cells, Mol. Pharmacol.
59 (2001) 127–134.
[118] R. Pacheco, J.M. Martinez-Navio, M. Lejeune, N. Climent, H. Oliva, J.M. Gatell, T.
Gallart, J. Mallol, C. Lluis, R. Franco, CD26, adenosine deaminase, and adenosine
receptors mediate costimulatory signals in the immunological synapse, Proc.
Natl. Acad. Sci. U. S. A. 102 (2005) 9583–9588.
[119] A. Lanzavecchia, F. Sallusto, Dynamics of T lymphocyte responses: intermediates,
effectors, and memory cells, Science 290 (2000) 92–97.
[120] Q.Y. Zhou, C. Li, M.E. Olah, R.A. Johnson, G.L. Stiles, O. Civelli, Molecular cloning
and characterization of an adenosine receptor: the A3 adenosine receptor, Proc.
Natl. Acad. Sci. U. S. A. 89 (1992) 7432–7436.
[121] C.A. Salvatore, M.A. Jacobson, H.E. Taylor, J. Linden, R.G. Johnson, Molecular
cloning and characterization of the human A3 adenosine receptor, Proc. Natl.
Acad. Sci. U. S. A. 90 (1993) 10365–10369.
[122] S. Gessi, S. Merighi, K. Varani, E. Leung, S. Mac Lennan, P.A. Borea, The A3
adenosine receptor: an enigmatic player in cell biology, Pharmacol. Ther. 117
(2008) 123–140.
[123] T.C. Wan, Z.D. Ge, A. Tampo, Y. Mio, M.W. Bienengraeber, W.R. Tracey, G.J.
Gross, W.M. Kwok, J.A. Auchampach, The A3 adenosine receptor agonist CP-
532,903 [N6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5′-N-methylcarboxa-
mide] protects against myocardial ischemia/reperfusion injury via the
sarcolemmal ATP-sensitive potassium channel, J. Pharmacol. Exp. Ther. 324
(2008) 234–243.
[124] M.H. Silverman, V. Strand, D. Markovits, M. Nahir, T. Reitblat, Y. Molad, I. Rosner,
M. Rozenbaum, R.Mader, M. Adawi, D. Caspi, M. Tishler, P. Langevitz, A. Rubinow,
J. Friedman, L. Green, A. Tanay, A. Ochaion, S. Cohen, W.D. Kerns, I. Cohn, S.
Fishman-Furman, M. Farbstein, S.B. Yehuda, P. Fishman, Clinical evidence for
utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis:
data from a phase II clinical trial, J. Rheumatol. 35 (2008) 41–48.
[125] M.L. Trincavelli, D. Tuscano, M. Marroni, K.N. Klotz, A. Lucacchini, C. Martini,
Involvement of mitogen protein kinase cascade in agonist-mediated human A(3)
adenosine receptor regulation, Biochim. Biophys. Acta 1591 (2002) 55–62.
[126] F. Santini, R.B. Penn, A.W. Gagnon, J.L. Benovic, J.H. Keen, Selective recruitment of
arrestin-3 to clathrin coated pits upon stimulation of G protein-coupled
receptors, J. Cell. Sci. 113 (Pt. 13) (2000) 2463–2470.
[127] G. Ferguson, K.R. Watterson, T.M. Palmer, Subtype-speciﬁc regulation of receptor
internalization and recycling by the carboxyl-terminal domains of the human A1
and rat A3 adenosine receptors: consequences for agonist-stimulated translo-
cation of arrestin3, Biochemistry 41 (2002) 14748–14761.
[128] V.P. Jaakola, M.T. Grifﬁth, M.A. Hanson, V. Cherezov, E.Y. Chien, J.R. Lane, A.P.
Ijzerman, R.C. Stevens, The 2.6 angstrom crystal structure of a human A2A
adenosine receptor bound to an antagonist, Science 322 (2008) 1211–1217.
